Matthew Bardin
Technik-/Wissenschafts-/F&E-Leiter bei Romark, L.C.
Profil
Matthew Bardin is currently the VP-Medical Affairs, Research & Development at Romark, L.C.
Prior to this, he was the Senior Vice President-Operations at NeuroBo Pharmaceuticals, Inc. from 2022 to 2023.
He holds a doctorate degree from Mcwhorter School of Pharmacy.
Aktive Positionen von Matthew Bardin
| Unternehmen | Position | Beginn |
|---|---|---|
Romark, L.C.
 Romark, L.C. Pharmaceuticals: MajorHealth Technology Romark LC is a pharmaceutical company, which engages in the development and commercialization of innovative small molecules for treating infectious diseases and cancers. It markets Alinia for Oral Suspension, a drug used for the treatment of diarrhea caused by Giardia lamblia or Cryptosporidium parvum in patients 12 months of age and older. The company was founded by Jean-François Rossignol and Marc S. Ayers in 1993 and is headquartered in Tampa, FL. | Technik-/Wissenschafts-/F&E-Leiter | 06.05.2022 |
Ehemalige bekannte Positionen von Matthew Bardin
| Unternehmen | Position | Ende |
|---|---|---|
| NEUROBO PHARMACEUTICALS, INC. | Geschäftsführer | 01.02.2023 |
Ausbildung von Matthew Bardin
| Mcwhorter School of Pharmacy | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| NEUROBO PHARMACEUTICALS, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Romark, L.C.
Romark, L.C. Pharmaceuticals: MajorHealth Technology Romark LC is a pharmaceutical company, which engages in the development and commercialization of innovative small molecules for treating infectious diseases and cancers. It markets Alinia for Oral Suspension, a drug used for the treatment of diarrhea caused by Giardia lamblia or Cryptosporidium parvum in patients 12 months of age and older. The company was founded by Jean-François Rossignol and Marc S. Ayers in 1993 and is headquartered in Tampa, FL. | Health Technology |
